Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Young Adult Survivors United
Duke University
Seattle Children's Hospital
Deciphera Pharmaceuticals, LLC
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)